AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19509109 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 67
Study 19509109 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 67
Study 19509109 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHA)
Number of subjects: 67
Study 19509109 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 67
Study 17991662 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma n-3 PUFA proportions
Number of subjects: 807
Study 10620209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 212
Study 10620209 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 212
Study 8859184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminder intervention
Number of subjects: 2368
Study 8859184 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder intervention
Number of subjects: 2368
Study 1644089 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (up to 150 mg/day for 6 weeks)
Number of subjects: 18
Study 1644089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6084121 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz 16 mg
Number of subjects: 12
Study 6084121 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (2 to 32 mg)
Number of subjects: 12
Study 6084121 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz 16 mg (sublingual and oral)
Number of subjects: 12
Study 6084121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31555926 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day normobaric hypoxic confinement (FiO2=0.14) with daily 90-min normoxic controlled hyperthermia (target rectal temperature: 38.5 °C)
Number of subjects: 8
Study 29969301 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine (400 mg)
Number of subjects: 28
Study 29969301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27125345 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 6466
Study 27125345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6466
Study 25078901 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control
Number of subjects: 24
Study 25078901 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 24
Study 23149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 44
Study 23149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 44
Study 23149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 200 mg
Number of subjects: 44
Study 23149929 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 44
Study 23149929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20336066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar (20, 50, 100, 300, 600, or 900 microg)
Number of subjects: 71
Study 20336066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar (doses >300 microg)
Number of subjects: 71
Study 20336066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18606930 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth attendant hand washing with soap and water before assisting with delivery
Number of subjects: 23662
Study 18606930 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hand washing with soap and water or antiseptic before handling the baby
Number of subjects: 23662
Study 18606930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined birth attendant and maternal hand washing
Number of subjects: 23662
Study 15826316 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation, followed by continuous 5-FU infusions for two more cycles.
Number of subjects: 110
Study 15826316 — intervention group
Group type: COMPARATOR
Intervention: 5-FU with intravenous bolus injections of folinic acid on 5 consecutive days every 28 days for 6 cycles.
Number of subjects: 110
Study 12186626 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0
Study 10404912 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19): tidal volume to obtain normal values of arterial carbon dioxide tension (35-40 mm Hg) and PEEP producing the greatest improvement in arterial oxygen saturation without worsening hemodynamics.
Number of subjects: 44
Study 10404912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective strategy group (n = 18): tidal volume and PEEP based on the volume-pressure curve.
Number of subjects: 44
Study 8624227 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP/DCPD dentifrice (1000 ppm fluoride)
Number of subjects: 12
Study 8624227 — intervention group
Group type: COMPARATOR
Intervention: MFP/silica dentifrice (1000 ppm fluoride)
Number of subjects: 12
Study 8624227 — intervention group
Group type: COMPARATOR
Intervention: DCPD placebo
Number of subjects: 12
Study 8624227 — intervention group
Group type: COMPARATOR
Intervention: Silica placebo
Number of subjects: 12
Study 8624227 — intervention group
Group type: COMPARATOR
Intervention: MFP/DCPD dentifrice (250 ppm fluoride)
Number of subjects: 12
Study 8624227 — intervention group
Group type: COMPARATOR
Intervention: MFP/DCPD dentifrice (0 ppm fluoride)
Number of subjects: 12
Study 1963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin 20 mg/m2
Number of subjects: 19
Study 1963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin 24 mg/m2
Number of subjects: 19
Study 1963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin 25 mg/m2
Number of subjects: 19
Study 1963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin 27 mg/m2
Number of subjects: 19
Study 1963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (all doses)
Number of subjects: 19
Study 31280990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 135
Study 31280990 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 135
Study 29684926 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG, n=15)
Number of subjects: 30
Study 29684926 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n=15)
Number of subjects: 30
Study 26194935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 28 days
Number of subjects: 403
Study 26194935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 26194935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (subgroup analysis for large stones 5 to 10 mm)
Number of subjects: 403
Study 26194935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup analysis for large stones 5 to 10 mm)
Number of subjects: 403
Study 26194935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 403
Study 24495883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary melatonin administration
Number of subjects: 40
Study 24495883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 23277643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oridermyl (acaricidal/antibiotic/ antifungal/anti‐inflammatory ointment), treated once daily for 10 days
Number of subjects: 24
Study 23277643 — intervention group
Group type: COMPARATOR
Intervention: Revolution (selamectin spot‐on), treated on Day 0
Number of subjects: 24
Study 21049628 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: Tpanax Notoginseng Pills PO, Lornoxicam For Injection, 8 mg IM
Number of subjects: 120
Study 21049628 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: Tpanax Notoginseng Pills PO, Tong Mai Decoctions 200 mL PO
Number of subjects: 120
Study 21049628 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV: Tpanax Notoginseng Pills PO, Lornoxicam For Injection 8 mg IM, Tong Mai Decoctions 200 mL PO
Number of subjects: 120
Study 21049628 — intervention group
Group type: COMPARATOR
Intervention: Group I: Tpanax Notoginseng Pills PO
Number of subjects: 120
Study 16945983 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component educational intervention delivered by health personnel as part of usual care; details on dosage and duration not specified.
Number of subjects: 0
Study 16945983 — intervention group
Group type: COMPARATOR
Intervention: Existing nutrition education (control group); details on dosage and duration not specified.
Number of subjects: 0
Study 17877120 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg/day, 25 mg/day, 50 mg/day) administered in increasing doses every four weeks
Number of subjects: 30
Study 17877120 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy subjects aged 39‐49 years, mean 45.7 years)
Number of subjects: 30
Study 12121506 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN and GMCSF (group A, n = 10)
Number of subjects: 24
Study 12121506 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN and lamivudine (group B, n = 14)
Number of subjects: 24
Study 12121506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sustained response
Number of subjects: 24
Study 10522506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride (0.5 mg/mL) nasal spray containing benzalkonium chloride (0.1 mg/mL)
Number of subjects: 35
Study 10522506 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline nasal spray without benzalkonium chloride
Number of subjects: 35
Study 7539822 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 7539822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 7539822 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 7539822 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive intervention
Number of subjects: 0
Study 7539822 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic implantable cardioverter-defibrillator
Number of subjects: 0
Study 7539822 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmic drugs
Number of subjects: 0
Study 7539822 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 1971461 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl-1 isoquinoline derivative (458 L)
Number of subjects: 12
Study 7027062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (2 micrograms daily for 3 months, then 1 microgram daily for 9 months)
Number of subjects: 48
Study 7027062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7027062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol
Number of subjects: 48
Study 31419239 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR(+) patients
Number of subjects: 13043
Study 31419239 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR(-) patients
Number of subjects: 13043
Study 31419239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for EGFR(+) patients
Number of subjects: 13043
Study 31419239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for EGFR(-) patients
Number of subjects: 13043
Study 25467077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195
Study 25467077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 195
Study 25467077 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 195
Study 22677612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic retention sutures
Number of subjects: 300
Study 22677612 — intervention group
Group type: COMPARATOR
Intervention: Control group (running looped #1 nylon suture)
Number of subjects: 300
Study 21270743 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) as preexposure prophylaxis (PrEP)
Number of subjects: 0
Study 21270743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19246334 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d (RSV10 group)
Number of subjects: 150
Study 19246334 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d (RSV20 group)
Number of subjects: 150
Study 19246334 — intervention group
Group type: COMPARATOR
Intervention: therapeutic lifestyle modification (nonstatin-treated group)
Number of subjects: 150
Study 17454156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily from cycle day 3 to day 7
Number of subjects: 33
Study 17454156 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg daily from cycle day 3 to day 7
Number of subjects: 33
Study 15114429 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micro g midazolam
Number of subjects: 21
Study 15114429 — intervention group
Group type: COMPARATOR
Intervention: ketoconazole (200 mg b.i.d.)
Number of subjects: 21
Study 15114429 — intervention group
Group type: COMPARATOR
Intervention: rifampicin (450 mg q.d.)
Number of subjects: 21
Study 11826546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 10, 20, and 40 mg as monotherapy
Number of subjects: 203
Study 9558043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 32
Study 8034781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel + SCRP
Number of subjects: 22
Study 8034781 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% tetracycline paste + SCRP
Number of subjects: 22
Study 8034781 — intervention group
Group type: COMPARATOR
Intervention: SCRP only
Number of subjects: 22
Study 2539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus dihydroergotamine mesylate (5,000 IU unfractionated heparin plus 0.5 mg dihydroergotamine mesylate twice daily)
Number of subjects: 200
Study 2539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin plus dihydroergotamine mesylate (1,500 IU low-molecular weight heparin plus 0.5 mg dihydroergotamine mesylate once daily)
Number of subjects: 200
Study 2539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin plus dihydroergotamine mesylate
Number of subjects: 200
Study 2539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus dihydroergotamine mesylate
Number of subjects: 200
Study 31990684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic CD4+ T cells
Number of subjects: 35
Study 31990684 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T cells
Number of subjects: 35
Study 31990684 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DR‐expressing endothelial cells
Number of subjects: 35
Study 31990684 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic cells
Number of subjects: 35
Study 30653123 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI)
Number of subjects: 644
Study 30653123 — intervention group
Group type: COMPARATOR
Intervention: Involved-field irradiation (IFI)
Number of subjects: 644
Study 29330978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 200
Study 29330978 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection for sensory blockade
Number of subjects: 200
Study 25490907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 84
Study 25490907 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 84
Study 23735819 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (average weekly doses ranging from 133 to 19,106 units/week)
Number of subjects: 1244
Study 23735819 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (middle tertile of Hb achieved >11.5 to <12.7 g/dl and lowest tertile of epoetin-alfa dose exposure level <5,164 units/week)
Number of subjects: 1244
Study 23735819 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (average weekly dose)
Number of subjects: 1244
Study 22189410 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education over a 4-week period with remote tutor facilitation
Number of subjects: 166
Study 22189410 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face traditional education using a 1-day seminar format with additional video and written support material
Number of subjects: 166
Study 19929119 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of sounds
Number of subjects: 35
Study 19929119 — intervention group
Group type: COMPARATOR
Intervention: No control of sounds
Number of subjects: 35
Study 16825039 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised nonaggravating exercise program
Number of subjects: 93
Study 16825039 — intervention group
Group type: COMPARATOR
Intervention: Usual surgical advice
Number of subjects: 93
Study 16422971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 732
Study 16422971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 732
Study 16422971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 16422971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10/20 mg
Number of subjects: 732
Study 11159876 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM26226 (5-500 microg. kg(‐1). h(‐1))
Number of subjects: 0
Study 9458563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 148
Study 9458563 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 148
Study 8166066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous-SQ pathways (right ventricular cathode to SQ anode and coronary sinus cathode to SQ anode)
Number of subjects: 42
Study 8166066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous-transvenous pathways (right ventricle to coronary sinus and right ventricle to superior vena cava)
Number of subjects: 42
Study 8166066 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial pathways
Number of subjects: 42
Study 3212422 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20
Study 3212422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 29864043 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling, manual therapy (MT), and exercise
Number of subjects: 242
Study 29864043 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling
Number of subjects: 242
Study 29864043 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MT) and exercise
Number of subjects: 242
Study 26186644 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of pitavastatin calcium
Number of subjects: 0
Study 26186644 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded formulation of pitavastatin calcium
Number of subjects: 0
Study 26186644 — intervention group
Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 0
Study 25559146 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Number of subjects: 60
Study 25559146 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine surgical care)
Number of subjects: 60
Study 23878024 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified grapefruit juice (GFJ) (240 mL)
Number of subjects: 18
Study 23878024 — intervention group
Group type: EXPERIMENTAL
Intervention: Original grapefruit juice (GFJ) (240 mL)
Number of subjects: 18
Study 23878024 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study 20185386 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 0.8 mg/kg (<= 50 mg) once weekly for 12 weeks
Number of subjects: 211
Study 20185386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 20185386 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 211
Study 18185506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels maintained in the target range of 150-300 pg ml(‐1)
Number of subjects: 0
Study 18185506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels less than 150 pg ml(‐1)
Number of subjects: 0
Study 18185506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels greater than 300 pg ml(‐1)
Number of subjects: 0
Study 18185506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biopsies performed at baseline and after 1 year follow-up
Number of subjects: 0
Study 17006065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 microg/kg
Number of subjects: 75
Study 17006065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 75
Study 17006065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg/kg
Number of subjects: 75
Study 17006065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg/kg
Number of subjects: 75
Study 17006065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12714797 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 43
Study 10514345 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0 administered intramuscularly (im)
Number of subjects: 41
Study 10514345 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0 administered subcutaneously (sc)
Number of subjects: 41
Study 10514345 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0
Number of subjects: 41
Study 10514345 — intervention group
Group type: COMPARATOR
Intervention: Animal-source glucagon (aG)
Number of subjects: 41
Study 8949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 micrograms/g once daily)
Number of subjects: 40
Study 8949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream twice daily
Number of subjects: 40
Study 8949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol and clobetasone 17-butyrate (0.5 mg/g) creams
Number of subjects: 40